Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Halozyme Therapeutics Inc (NASDAQ:HALO)

12.09
Delayed Data
As of Sep 23
 -0.31 / -2.50%
Today’s Change
6.96
Today|||52-Week Range
18.65
-30.24%
Year-to-Date
Bullish & Bearish Reversals for the Week
Sep 19 / TheStreet.com - Paid Partner Content
Netflix Can Break out Soon
Sep 19 / TheStreet.com - Paid Partner Content
Halozyme Therapeutics (HALO) Catches Eye: Stock Up 7.9%
Sep 19 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close12.40
Today’s open12.38
Day’s range12.07 - 12.47
Volume1,568,635
Average volume (3 months)1,342,437
Market cap$1.6B
Dividend yield--
Data as of 3:59pm ET, 09/23/2016

Growth & Valuation

Earnings growth (last year)+55.36%
Earnings growth (this year)-263.75%
Earnings growth (next 5 years)--
Revenue growth (last year)+79.28%
P/E ratioNM
Price/Sales16.26
Price/Book36.03

Competitors

 Today’s
change
Today’s
% change
FPRXFive Prime Therapeut...+0.32+0.59%
XLRNAcceleron Pharma Inc-0.50-1.25%
CHRSCoherus BioSciences ...-0.88-2.85%
ONCESpark Therapeutics I...-1.99-3.20%
Data as of 3:59pm ET, 09/23/2016

Financials

Next reporting dateNovember 7, 2016
EPS forecast (this quarter)-$0.26
Annual revenue (last year)$135.1M
Annual profit (last year)-$32.2M
Net profit margin-23.86%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
--, --

Forecasts

Search for Jobs